Fig. 2From: Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research AllianceRanking of biologics. Respondents were asked to rank the above biologic therapies in order of preference from 1 (first preference) to 5 (last preference). By weighted average, respondents favored rituximab (1.45) followed by abatacept (2.42), tocilizumab (3.07), infliximab (3.08), and other (3.77)Back to article page